Novel Approaches Under Evaluation in Gastrointestinal Stromal Tumors | Supplements and Featured Publications

January 17, 2024

Robin Jones, MD, MRCP, discusses the importance of communication between community and academic oncologists in cancer care.

December 05, 2023

Gloria Marquina, MD, PhD, as well as the need to consider ongoing clinical trials for patients with gastrointestinal stromal tumors vs treatment with the current second-line standard-of-care agent sunitinib.

November 21, 2023

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

November 07, 2023

Neeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.

October 25, 2023

The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.

October 10, 2023

Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.

September 18, 2023

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.